References
- Garcia‐Marcos L, Schuster A, Perez‐Yarza E. Benefit‐risk assessment of antileukotrienes in the management of asthma. Drug Safety 2003; 26(7)483–518, [CSA]
- Sass D A, Chopra K B, Wu T. A case of montelukast‐induced hepatotoxicity. Am J Gastroenterol 2003 Mar; 98(3)704–705, [CROSSREF]
- Wechsler M E, Finn D, Gunawardena D, Westlake R, Barker A, Haranath S P, Pauwels R A, Kips J C, Drazen J M. Churg–Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000 Mar; 117(3)708–713, [CROSSREF]
- Sabio J M, Jimenez‐Alonso J, Gonzalez‐Crespo F. More about Churg–Strauss syndrome and montelukast treatment. Chest 2001 Dec; 120(6)2116, [CROSSREF]
- Guilpain P, Viallard J F, Lagarde P, Cohen P, Kambouchner M, Pellegrin J L, Guillevin L. Churg–Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002 May; 41(5)535–539, [CROSSREF]
- Geller M, Melo L R, Coutinho S V. Successful outcome of montelukast overdosage in an asthmatic child. Ann Allergy Asthma Immunol 2000 Mar; 84(3)370, [CSA]
- Cobb D B, Abbott C L, Watson W A, Fernandez M C. High‐dose montelukast exposures in a 3‐year‐old and a 5‐year‐old child. Vet Hum Toxicol 2002 Apr; 44(2)91–92, [CSA]